Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · IEX Real-Time Price · USD
34.65
-0.17 (-0.49%)
At close: Jul 19, 2024, 4:00 PM
34.66
+0.01 (0.03%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Vera Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Vera Therapeutics stock have an average target of 42.86, with a low estimate of 25 and a high estimate of 68. The average target predicts an increase of 23.69% from the current stock price of 34.65.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 31, 2024.
Analyst Ratings
The average analyst rating for VERA stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $60 → $65 | Buy | Maintains | $60 → $65 | +87.59% | May 31, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $57 → $68 | Strong Buy | Maintains | $57 → $68 | +96.25% | May 10, 2024 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +61.62% | Apr 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $27 → $56 | Strong Buy | Maintains | $27 → $56 | +61.62% | Mar 27, 2024 |
| Wedbush | Wedbush | Hold Maintains $21 → $34 | Hold | Maintains | $21 → $34 | -1.88% | Mar 21, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.34
from -2.25
EPS Next Year
-2.50
from -2.34
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 85.8M | 323.0M | 653.0M |
| Avg | n/a | n/a | 40.8M | 165.9M | 399.4M |
| Low | n/a | n/a | 7.7M | 79.7M | 210.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 692.5% | 293.6% |
| Avg | - | - | - | 307.1% | 140.7% |
| Low | - | - | - | 95.4% | 26.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.01 | -2.14 | -2.22 | 0.20 | 2.37 |
| Avg | -2.34 | -2.50 | -2.63 | -0.19 | 1.95 |
| Low | -2.55 | -3.24 | -3.03 | -0.40 | 1.53 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.